Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …

Proliferation is an important part of cancer development and progression. This is manifest by
altered expression and/or activity of cell cycle related proteins. Constitutive activation of …

Emerging evidence indicates that various cancers can gain resistance to targeted therapies
by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations …

Exercise is recognized by clinicians in the field of clinical oncology for its potential role in
reducing the risk of certain cancers and in reducing the risk of disease recurrence and …

The normal development and maintenance of the prostate is dependent on androgen acting
through the androgen receptor (AR). AR remains important in the development and …

The androgen receptor (AR), ligand-induced transcription factor, is expressed in primary
prostate cancer and in metastases. AR regulates multiple cellular events, proliferation …

Signal transducers and activators of transcription (STATs) were identified originally as key
components of cytokine signaling pathways. More recently, constitutive activation of STAT …

Prostate cancer is the second most prevalent cancer in males in the United States. Standard
therapy relies on removing, or blocking the actions of, androgens. In most cases, this therapy …

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer
(CRPC) patients' survival an extra 4.8 months, it might also result in some adverse effects via …

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to
be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to …